dr. camidge on the alta study of brigatinib in nsclc
Published 6 years ago • 660 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
6:19
ross camidge: brigatinib for adult patients with alk metastatic non-small cell lung cancer
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
1:35
d. ross camidge discusses the development of a new lung cancer drug
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
4:18
dr. ross camidge on the ever changing world of clinical cancer research
-
2:13
alk nsclc: brigatinib indication and alta trial
-
1:27
dr. camidge on the keynote-024 trial in nsclc
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:24
dr. halmos on the implications of the ipass study in lung cancer
-
1:29
dr. camidge on the unmet needs for lung cancer